General Flynn | Who Is Vivek Ramaswamy? How Did Vivek Ramaswamy Become a Billionaire? 28 Facts About RamaSWAMPy? + Why Did Ramaswamy Team Up With Pfizer? What Are Ramaswamy's Thoughts On Chimeras? (See Description for Supporting Facts)
Learn How to Protect Your Wealth Against Inflation & Central Bank Digital Currencies HERE: www.BH-PM.com
Learn More About General Flynn Today HERE: www.GeneralFlynn.com
Learn More About Tom Renz Today HERE: www.TomRenz.com
Learn More About Charlie Carbone HERE:
FACT #21 - 2023 (Age 38) Roivant Loses Copious Amounts of Money Year After Year | Virtually All of Ramaswamy’s Companies Consistently Lose Money And None Have Ever Turned a Profit Consistently
2023 - Roivant Is Predicted to Lose Another $1.03 Billion According to Bloomberg / Fortune - https://fortune.com/2023/06/14/vivek-ramaswamy-is-threatening-gop-heavyweights-in-the-polls-but-his-business-record-doesnt-live-up-to-the-hype/
2022 - Roivant Lost $1.12 Billion In 2022
2021 - Roivant Lost $698 Million In 2021
2020 - Roivant Lost $433 Million In 2020
FACT #20 - 2023 - (Age 38) Roivant Set Up a New Subsidiary, Telavant, to Advance the Asset. Pfizer Owns 25% of Telavant and Retains the Rights to RVT-3101 Outside of the U.S. and Japan. According to the WSJ, Roche is Nearing a Deal to Buy Roivant's Rights to the Molecule - https://www.fiercebiotech.com/biotech/roche-lining-7b-roivant-deal-join-merck-co-bowel-disease-race-wsj#:~:text=Roivant%20set%20up%20a%20new,Roivant's%20rights%20to%20the%20molecule.
FACT #19 - 2023 - (Age 38) Vivek Ramaswamy’s Pharmacy Firm to Sell Experimental Drug In $7B Deal - READ -
https://nypost.com/2023/07/14/vivek-ramaswamy-founded-company-to-sell-drug-in-7b-deal/
FACT #18 - 2022 (June 28) - (Age 37) Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus - https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing
FACT #17 - 2022 - (Age 37) As Recently As February 2022, Ramaswamy’s Roivant Listed Subsidiary Companies In China, According to SEC Filings:
FACT #16 - 2022 - (Age 37) Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases - https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-form-new-vant-company-focused-developing
FACT #15 - 2021 - (Age 36) Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics | Silicon Therapeautics Provides Physics-Based Approaches At to Be Integrated with Machine Learning-Based Approaches at VantAI - READ - https://www.businesswire.com/news/home/20210226005291/en/Roivant-Grows-Computational-Drug-Discovery-Engine-with-Acquisition-of-Silicon-Therapeutics
Share this post